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Abstract
Complex regional pain syndrome (CRPS) is a debilitating condition affecting the limbs that can be induced by surgery
or trauma. This condition can complicate recovery and impair one’s functional and psychological well-being. The wide
variety of terminology loosely used to describe CRPS in the past has led to misdiagnosis of this condition, resulting in
poor evidence-base regarding the treatment modalities available and their impact. The aim of this review is to report
on the recent progress in the understanding of the epidemiology, pathophysiology and treatment of CRPS and to
discuss novel approaches in treating this condition.
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Background
Complex regional pain syndrome (CRPS) is a chronic
neurological condition involving the limbs that is char-
acterised by severe pain along with sensory, autonomic,
motor and trophic impairment [1, 2]. This condition
may be induced by surgery, trauma or minor injury and
has a varying course, ranging from mild and self-limit-
ing, to chronic disease, which impairs activities of daily
living and health-related quality of life. The occurrence
of CRPS following elective or emergency extremity sur-
gery may complicate recovery and post-operative man-
agement. This increases the probability of a poorer
outcome and exerts a large financial burden on the
healthcare system. Due to the complexity and broad
spectrum of symptoms, patients with CRPS require
input from various clinical specialties including ortho-
paedic surgeons, anaesthetists, rheumatologists and
rehabilitation physicians. This mini-review aims to
provide an update on the recent progress in the under-
standing of the epidemiology, pathophysiology and treat-




CRPS is a clinical diagnosis made based on the findings
during the history and physical examination of the
patient, for which diagnostic criteria including the
Orlando Criteria for Complex Regional Pain Syndrome
and The Budapest Clinical Diagnostic Criteria for
Complex Regional Pain Syndrome by the International
Association for the Study of Pain (IASP) have been
developed [1]. CRPS can be classified into two types:
CRPS types I and II that are characterised by the absence
or presence of identifiable nerve injury. CRPS type I is a
syndrome that usually develops after an initiating noxious
event, is not limited to the distribution of a single
peripheral nerve, and is disproportionate to the inciting
event. It is associated with oedema, changes in skin blood
flow, abnormal sudomotor activity in the region of the
pain, allodynia and hyperalgesia and commonly involves
the distal aspect of the affected extremity or with a distal
to proximal gradient. CRPS type II can be defined as a
burning pain, allodynia and hyperpathia occurring in a
region of the limb after partial injury of a nerve or one of
its major branches innervating that region [1, 2].
Epidemiology
Overview
Although the diagnostic criteria for CRPS were put for-
ward in 1994, limited data from epidemiological studies
are available before 2000. Sandroni et al. conducted the
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first population-based study of CRPS in 2003, where
they reviewed and validated potential cases of CRPS of
the local population of Olmsted County over a 10-year
period using the IASP and Harden criteria [3]. The inci-
dence rate of CRPS type I was 5.46 per 100000 person-
years, and the incidence rate of CRPS type II was 0.82
per 100000 person-years, giving rise to a combined
incidence rate for both CRPS types I and II of 6.28
per 100000 person-years. However, a subsequent
population-based study by de Mos et al. estimated the
combined incidence rate of CRPS to be approximately
four times greater at 26.2 per 100000 person-years [4].
This has been attributed to differences in ethnic and
socio-economic background of the cohort as well as the
application of the diagnostic criteria. In contrast to
Sandroni et al., the study by de Mos et al. did not require
all cases to fulfil the diagnostic criteria but instead
retained cases based on confirmation of the diagnosis by
the general practitioner or specialist. Furthermore, the
retrospective application of the IASP criteria to informa-
tion on electronic charts as performed by Sandroni et al.
may have been overly strict. CRPS occurs most frequently
in individuals aged between 61 and 70 years and demon-
strates a female predilection, affecting three times more
females than males [4]. There appears to be an increased
preponderance for the upper limbs with a ratio of 3:2
compared to the lower limbs. Risk factors for this
condition include menopause, individuals with a history
of migraine, osteoporosis, asthma and angiotensin-
converting enzyme (ACE) inhibitor therapy and individuals
with an elevated intracast pressure due to a tight case or
extreme positions [5–7]. Furthermore, the prognosis of
CRPS is poorer in smokers compared to non-smokers [8].
Surgery
The development of CRPS following surgery is a major
cause of concern as this complicates post-operative
management and has significant clinical ramifications.
As such, rapid diagnosis and treatment are required to
prevent the sequelae such as swelling, atrophy, osteopor-
osis, pseudo-arthrosis, joint stiffness and tendon adhe-
sions. Operative procedures of the shoulder, distal
radius, carpal tunnel and Dupuytren’s contracture have
been shown to be associated with the manifestation of
CRPS. The incidence of CRPS following shoulder, distal
radius, carpal tunnel and Dupuytren’s contracture sur-
gery is estimated to be between 0.9 and 11%, 22 to 39%,
2 to 5% and 4.5 to 40%, respectively (Table 1) [9–18].
Although less studied, surgical treatment of the lower
limb is also associated with the development of CRPS. In
a prospective study of patients with tibial fractures, the
incidence of CRPS following surgical repair was docu-
mented at 31%; 33.3% of patients treated with intrame-
dullary nailing, 28.6% of patients treated with nails and
screws and 28.6% of patients treated with external
fixation [19]. A recent retrospective study by Rewhorn et
al. evaluating the occurrence of CRPS following elective
ankle and foot surgery in 390 patients found the overall
incidence to be 4.4%; 3.6% for CRPS type I and 1.8% for
CRPS type II [18]. Studies investigating the incidence of
CRPS following orthopaedic surgery have been limited
by the size of the cohort, thus, making it difficult to
draw a reliable estimate regarding the true prevalence of
this syndrome. Furthermore, findings from the majority
of these studies are highly susceptible to a type I error
due to the lack of a gold standard diagnostic criteria in
diagnosing this condition.
Fracture
Fractures appear to be a common inciting event for the
development of CRPS. A recent study by Beerthuizen et
al. investigated the occurrence of CRPS type I after 1 year
in 596 patients who had suffered fractures of the upper
or lower extremity [20]. In this study, the overall inci-
dence of CRPS type I was 7.0, with 15.2% of cases occur-
ring after ankle fracture, 2.9% following fifth metatarsal
fracture and 7.9% after wrist fracture. No cases of CRPS
were described following scaphoid fractures in this
study. It is apparent however that the incidence of CRPS
varies widely between studies. For instance, the develop-
ment of CRPS following fractures of the distal radius is
reported to range between 1 and 37% (Table 2) [19–24]. In
contrast to fractures of the upper extremity, there is
limited evidence regarding the incidence of CRPS
following fractures of the lower extremity. The only
other study to date was conducted by Sarangi et al.,
who reported an incidence of 30% in their cohort of
30 patients with tibial fractures treated with plaster
casts [19]. In most of these patients, the symptoms
Table 1 Reported incidence of CRPS following surgical procedures
of the upper and lower limb
Region Operation Study Incidence
Upper limb Shoulder Chalmers et al. 2014 [9] 11.1% (1:8)
Arndt et al. 2012 [10] 3.0% (3:97)
Gonzalez et al. 2011 [11] 0.9% (35:3975)
Bishop et al. 2005 [127] 1.3% (1:79)
Borgeat et al. 2001 [12] 1.0% (5:516)
Carpal tunnel
release
Shinya et al. 1995 [13] 1.9 (2:105)
Litchman et al. 1979 [14] 5.0% (5:95)
MacDonald et al. 1978 [15] 2.2% (4:182)
Dupuytren’s
contracture
Lily and Stern 2010 [16] 2.0% (1:49)
Bulstrode et al. 2005 [17] 2.4% (6:247)
Lower limb Tibial Sarangi et al. 1993 [19] 31% (9:20)
Ankle and
foot
Rewhorn et al. 2014 [18] 4.4% (17:373)
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resolved within 6 months. Despite a substantial amount
of data available regarding the incidence of CRPS, a wide
variability in findings persists. This can be attributed to in-
consistencies in diagnostic criteria used. For instance,
Beerthuizen et al. reported marked differences in the
number of patients diagnosed with the IASP, Veldmen
and Harden and Bruehl criteria, all of which were utilised
prior to the introduction of the Budapest criteria for CRPS
[20]. As such, it is likely that the differences in sensitivities
of these criteria are likely to result in varying rates of mis-
diagnosis. Moreover, data available from these studies have
been limited solely to CRPS type I, and as such, more
work is needed to elucidate the incidence of CRPS type II.
Pathophysiology
Inflammation
The clinical presentation of the acute phase of CRPS
supports the hypothesis that the development of this
condition is due to an exaggerated inflammatory response
to trauma. Clinical findings of the CRPS-affected limb
reveal pain, oedema, erythema, increased temperature
and impaired function—the five cardinal signs of
inflammation [25]. Tissue trauma triggers the release
of pro-inflammatory cytokines such as interleukin(IL)-1β,
IL-2, IL-6 and tumour necrosis factor-α (TNF-α)
along with neuropeptides including calcitonin gene-
related peptide, bradykinin and substance P. These
substances increase plasma extravasation and vaso-
dilation, producing the characteristic features of acute
CRPS [26, 27].
Altered cutaneous innervation
Initial neuronal injury, however imperceptible has been
implicated as an important trigger in the development of
both CRPS types I and II [28]. This has been supported by
studies demonstrating a reduction in C-type and Aδ-type
cutaneous afferent neuron fibre density in the CRPS-
affected limb compared to the unaffected limb, with these
changes primarily affecting nociceptive fibres [29, 30]. The
decrease in C-type and Aδ-type fibres was associated with
an increase in aberrant fibres of unknown origin, and it
has been postulated that the exaggerated pain sensation
may be due to altered function of these fibres [30]. One
animal study on rats has shown a causal relationship
between this neuronal trigger and a reduction in neuron
fibre density, highlighting the possibility that altered
cutaneous innervation of the CRPS-affected limbs may be
a result of an initial neuronal injury [31]. Human studies,
however, have been unable to replicate this causative
effect, thus, bringing into question whether the reduction
in neuron fibre density is an epiphenomenon rather than
being directly related to the condition.
Central and peripheral sensitisation
Following tissue damage and/or neuronal injury,
alterations in the central and peripheral nervous systems
lead to increased inflammation, and an enhanced re-
sponsiveness to pain. These adaptations act as protective
mechanisms to promote avoidance of activities that
cause further injury. Within the central nervous system
(CNS), persistent and intense noxious stimulation of
peripheral nociceptive neurons results in central sensi-
tisation. Accordingly, there is alteration in nociceptive
processing in the CNS and increased excitability of
secondary central nociceptive neurons in the spinal cord.
This is mediated by the release of neuropeptides such as
substance P, bradykinin and glutamate by peripheral
nerves, which sensitise and increase the activity of local
peripheral and secondary central nociceptive neurons
resulting in increased pain from noxious stimuli (hyper-
algesia) and pain in response to non-noxious stimuli
(allodynia) [26, 32, 33]. Research has shown that CRPS
patients have a significantly greater windup to repeated
stimulation of the affected limb compared to the contra-
lateral limb or other limbs [34, 35].
Altered sympathetic nervous system function
In the chronic (cold) phase of the clinical course of
CRPS, the CRPS-affected limb is cyanosed and clammy
as a result of vasoconstriction and sweating. This
suggests that excessive sympathetic nervous system out-
flow is a driving factor in progression of the condition
and maintenance of the pain [36]. Animal studies have
observed adrenergic receptor expression on nociceptive
fibres following nerve trauma, which may provide a
possible mechanism of the sympathetically induced pain.
In addition, expression of adrenergic receptors on noci-
ceptive fibres following injury may contribute to
sympatho-afferent coupling increasing the pain intensity
Table 2 Reported incidence of CRPS following fractures of the
upper and lower limbs
Region Antecedent Event Study Incidence
Upper limb Distal radius
fracture
Jellad et al. 2014 [21] 32.2% (29:61)
Dijkstra et al. 2003 [22] 1.1% (1:87)
Colles’ fracture Bickerstaff and Kanis
1994 [23]
28.1% (77:197)
Atkins et al. 1990 [24] 36.7% (22:38)








Lower limb Tibial fracture Sarangi et al. 1993 [19] 30% (9:21)
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[28]. This has been demonstrated in patients with sym-
pathetically mediated CRPS pain where high sympathetic
nervous system activity increased spontaneous pain by
22% and increased the spatial extent of dynamic and
punctate hyperalgesia by 42 and 27% respectively [37].
Circulating catecholamines
Variation in the clinical features of CRPS as the condi-
tion progresses from the acute (warm) phase to the
chronic phase may be attributed to alterations in cate-
cholaminergic mechanisms [28]. During the acute phase,
the CRPS-affected limb demonstrates a reduction in the
levels of circulating plasma norepinephrine compared to
the unaffected limb [38]. As a result, there is compensa-
tory upregulation of peripheral adrenergic receptors
causing supersensitivity to circulating catecholamines
[39]. Consequently, excessive vasoconstriction and
sweating occurs following exposure to catecholamines,
giving rise to the characteristic cold and blue extremity
seen during the chronic phase.
Autoimmunity
The presence of immunoglobulin G (IgG) autoantibodies
against surface antigens on autonomic neurons in the
serum of patients with CRPS suggests that autoimmun-
ity may play a role in the development of this condition
[40, 41]. This is supported by the results of a small pilot
trial where patients with CRPS who were given intraven-
ous immunoglobulin treatment demonstrated a signifi-
cant reduction in pain symptoms when compared with
those given a placebo [42].
Brain plasticity
Neuroimaging studies of patients with CRPS have dem-
onstrated a decrease in area representing the CRPS-
affected limb in the somatosensory cortex compared to
the unaffected limb [43, 44]. The sensory representation
of the affected limb, as part of the Penfield homunculus
is distorted, with shrinkage and shifting of the area [43].
The extent of reorganisation bears significant correlation
with the pain intensity and degree of hyperalgesia expe-
rienced by the patient, and these alterations return to
normal following successful CRPS treatment [43, 45, 46].
Genetic factors
Although there is a lack of consensus regarding the in-
fluence of genetic factors in CRPS, family studies have
suggested a genetic preponderance towards developing
this condition. Siblings of CRPS patients under 50 years
were at three times higher risk of developing the condi-
tion, with a mitochondrial inheritance pattern [47, 48].
Furthermore, the genes of the major histocompatibility
complex encoding the human leukocyte antigen (HLA)
molecules, HLA-B62 and HLA-DQ8 alleles were found
to strongly correlate with the development of CRPS [49].
Psychological factors
Due to the prevalence of anxiety and depression in
patients with CRPS and the unusual nature of symp-
toms, psychological factors have been hypothesised to
play a role in the development or propagation of CRPS.
Puchalski et al. observed a higher occurrence of CRPS
following fractures of the distal radius in elderly patients
with psychological and/or psychiatric illness, thereby im-
plicating the role of psychological factors [50]. However,
evidence regarding this remains inconclusive as other
studies have failed to confirm this association, and a
definitive causation has yet to be identified [28].
Management
Physical and occupational therapy
Physical and occupational therapy is a key component of
the rehabilitation process in patients with CRPS and is
recommended as the first-line treatment. Patients can
develop kinesophobia and the aim of therapy is to over-
come this fear of pain and enable the patient to gain the
best functional use of the limb. This program is tailored
specifically to each individual and can involve multiple
modalities. These include elevation, massage, contrast
baths, transcutaneous electrical nerve stimulation, gentle
range of motion, isometric strengthening exercise and
stress loading of the affected limb along with provision of
adequate analgesia. Occupational therapy encourages use
of the affected limb in activities of daily living. The use of
specialised garments or wrappings may reduce oedema
and sensory overload of the affected limb. Mirror box
therapy has been shown to reduce neuropathic pain and
improve two-point sensation in the affected limb [51].
Psychological therapy
Chronic pain affects the health-related quality of life and
places a huge emotional and psychological burden on pa-
tients. Thus, it is essential for newly diagnosed patients
with CRPS to have a discussion with a psychological care
provider regarding their condition and its progression as
well as the need for active self-management and participa-
tion in a care plan. This can be followed up with cognitive
behavioural therapy, learning relaxation skills and biofeed-
back to facilitate rehabilitation, reduce pain intensity and
provide patients with more control. It is important to
assess and treat patients for concomitant axis I disorders
such as major depression, generalised anxiety disorder
and post-traumatic stress disorder, which may complicate
the rehabilitation process.
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Medical management
Corticosteroids and non-steroidal anti-inflammatory
drugs (NSAIDs) reduce inflammation and have been
used in the treatment of CRPS. Randomised controlled
trials (RCTs) and case series have reported significant
improvements in pain and range of motion in the affected
limb following treatment with both oral and intramuscular
corticosteroid regimens [52–56]. However, it is evident
that these improvements are not experienced by all
patients suffering from CRPS, which may be attributed to
the multifactorial and heterogeneous nature of the condi-
tion [57]. There is currently no evidence of clinically posi-
tive effects following treatment with NSAIDs.
The use of anti-oxidants in the treatment of CRPS has
been based on the perception that oxygen free radicals
generated by the inflammatory process may be a key
component of the propagation of the disease process.
Topical preparations of anti-oxidants such as dimethyl
sulfoxide (DMSO) and N-acetylcysteine have shown suc-
cess in providing pain relief [58, 59]. The significant pre-
ventative effect of vitamin C in halting the transition to
CRPS can be attributed to its anti-oxidant properties
[60, 61]. Vitamin C is currently established as the most
efficacious preventative therapy for the development of
CRPS and is commonly used perioperatively following
extremity surgery [62, 63].
Anti-convulsant drugs such as gabapentin have demon-
strated evidence of effectiveness in providing pain relief in
acute and chronic neuropathic are commonly used as part
of the pharmacological management of CRPS [64, 65].
Studies investigating the efficacy of gabapentin in CRPS
type I have reported marked improvements in pain reduc-
tion and long-term sensory deficits, thereby supporting
the utility of this form of therapy [66, 67]. Although gaba-
pentin has a good safety profile, it is important to be
aware of the rare but severe side effects including mood
disorders and suicide ideation [68]. Although there is no
evidence supporting the long-term effectiveness of anti--
convulsants for CRPS, these agents may be useful in pro-
viding pain relief in the earlier stage of the disease.
The upregulation of inflammatory pathways in CRPS
sensitises excitatory nociceptive pathways that use N-
methyl-D-aspartic acid (NMDA) as a neurotransmitter
[69]. The central sensitisation and alteration of brain
plasticity that occurs could potentially be reversed with
the use of the NMDA receptor antagonist ketamine,
which can be administered topically or intravenously.
Placebo-controlled studies have shown both topical and
intravenous administration of ketamine to be effective at
alleviating pain and inducing complete remission in
treatment resistant patients, thereby highlighting the
potential of this approach [70–73]. However, side effects
including feelings of inebriation, nausea, vomiting, head-
aches and psychomimetic effects are highly prevalent,
and these have hindered the application of ketamine in
treating CRPS [74].
Sympathetically mediated pain in CRPS has led to the
studies investigating the role adrenergic receptor antago-
nists or alpha-2 adrenergic agonists in treating this con-
dition. Phenoxybenzamine has shown success in
providing complete pain remission, with increased ef-
fectiveness when administered in the acute stage, thus
emphasising the importance of early recognition of
CRPS [75, 76]. There have also been case reports of the
efficacy of this approach in patients in whom alternative
therapies have failed, although these have been limited
to small patient numbers [77]. Alternatively, clonidine,
which is an alpha-2 adrenergic agonist, has been
reported to relieve localised hyperalgesia and provide
extensive analgesia in patients with sympathetically me-
diated pain [78].
Several treatment strategies have also been used in
managing the chronic stage of CRPS. Calcium-channel
blockade with nifedipine has been reported to be effective
in managing the vasoconstriction occurring in this phase
of CRPS [76, 79]. Additionally, the use of gamma-
aminobutyric acid-β (GABA) agonist such as baclofen has
also been effective in reducing dystonia and pain while im-
proving functionality and quality of life in patients with
chronic CRPS [80–82]. A recent study looking into com-
bined neuromodulation with baclofen as an adjunct to
spinal cord stimulation (SCS) therapy demonstrated
effectiveness in decreasing pain intensity and dystonia,
suggesting the need for further larger scale trials [83].
As CRPS progresses, there is localised bone resorption
and remodelling, which can lead to nociceptive bone pain,
osteopenia and osteoporosis. In addition, reduction in
bone mineral density occurs as a result of lack of use of
the affected limb. Calcitonin preserves bone mass, has
effects on microvasculature and has anti-nociceptive ef-
fects, which have been found to be effective in treating
acute and chronic pain [84–86]. Bisphosphonates inhibit
osteoclasts, slowing down bone resorption and increasing
bone mineral density and are well-established to be effect-
ive at providing pain relief [87–91]. A review in 2010 con-
cluded bisphosphonates as the only medications with
clear benefits in treating CRPS [92]. One long-term
complication of bisphosphonate therapy is the develop-
ment of pathologic fractures, which is thought to be due
to compromise in microstructural properties of bone aris-
ing from the accumulation of microcracks [93]. However,
CRPS patients only require a few months of treatment
and therefore, are at minimal risk. Bisphosphonates are
contraindicated in patients with decreased renal function,
oesophageal motility disorders, peptic ulcer disease and
poor dentition. As there is the risk of jaw osteonecrosis,
patients should be told to report any tooth, jaw, face or
head discomfort during treatment [68, 94].
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There are contrasting views regarding the use of
opioid therapy in the treatment of CRPS. While opioid
therapy is useful in the acute phase of tissue injury,
long-term use for both peripheral and central neuro-
pathic pain is less efficacious and requires larger doses
[95]. Although the safety and effectiveness of opioids in
treating neuropathic pain have been documented, higher
doses and long-term use can result in tolerance, addic-
tion, misuse, immunosuppression, endocrine dysfunction
and overdoses leading to death [96].
The discovery of autoantibodies against adrenergic
receptors suggesting that CRPS has an autoimmune
component provides the basis for the use of intravenous
immunoglobulin (IVIG), which is a potent anti-
inflammatory and immune-modulator [40, 41]. A RCT
of 13 patients with chronic CRPS comparing low-dose
IVIG with intravenous normal saline reported pain relief
in the 12 patients who completed the trial at 6–19 days
following treatment [42].
Anaesthesia therapy
An alternative approach studied involves the use of
sympathetic blockade, which has diagnostic and thera-
peutic benefits. Sympathetic blocks aim to alleviate the
sympathetically mediated pain and can be used in
combination with botulinum toxin to prolong the
duration of analgesia. Recent evidence has shown sym-
pathetic blockade to provide substantial pain reduction
as well as longer analgesic duration, which enable
patients to improve participation in functional therapies
[97–99]. However, there remains a lack of definitive evi-
dence regarding the efficacy of sympathetic blockade
overall, and this approach has yet to be shown to be
curative [100].
Surgical management
Neuromodulation may also play a role in treating CRPS, es-
pecially in patients in unresponsive to sympathetic block-
ade. One RCT reported SCS and physiotherapy to be
significantly more effective at pain relief compared with
physiotherapy on its own at 6 months and 2 years although
this effectiveness diminished at long-term follow up of
5 years [101]. However, the prevalence of complications is
high, including lead displacement, pulse-generator pocket
revision, pulse-generator failure and infection [102, 103]. In
the majority of patients, SCS is associated with sustained
improvements in functional capability, quality of life,
depression and pain levels [103, 104].
Sympathectomy can be performed as an extension of
temporary sympathetic blockade in patients who have
good but transient relief from sympathetic blockade.
This involves severing the sympathetic chains or stellate
ganglion using chemicals, radiofrequency or open surgical
techniques to prolong analgesia. Chemical sympathectomy
is carried out using alcohol or phenol injections to destroy
the sympathetic chain but this method has variable
outcomes with limited evidence to support its effective-
ness [105]. Radiofrequency sympathectomy provides a
longer lasting pain relief, with 40% of patients reporting
greater than 50% pain reduction after a year [106].
Complications of sympathectomy are common such as
post-sympathectomy neuralgia, anhydrosis and Horner’s
syndrome. Given the permanent nature of this approach,
sympathectomy is generally considered only in patients
where alternative treatment options have failed.
Amputation in CRPS may be indicated due to pain, limb
dysfunction, gangrene, infection or ulcers [107]. The
majority of patients report a reduction in pain along with
improvements in mobility and sleep following amputation
of the affected limb, but many suffer from phantom pain
and recurrence in the residual limb [107, 108].
Emerging treatments
Immunomodulation
Chronic regional and neurogenic inflammation are
thought to play a key role in the initiation and propaga-
tion of CRPS [28, 109]. Patients suffering from this con-
dition display systemic elevation of pro-inflammatory
cytokines and a corresponding reduction in the anti-
inflammatory cytokine IL-10 [110]. Anti-cancer drugs
such as lenalidomide and thalidomide possess anti-
inflammatory and immunomodulatory effects and have
shown promise in alleviating this condition. In the open-
label study of thalidomide, pain relief was reported in
approximately one-third of the participants, which was
evident within 4 to 6 weeks of treatment commencing
[111]. Similarly, patients receiving lenalidomide reported
significant improvements in pain and functional scores
within 12 weeks, which persisted for one year [112].
Promisingly, patients accruing the greatest benefit from
these agents are those with very high pain scores and
treatment-refractory disease. Despite the recent failure
of the phase IIb trial of lenalidomide to show any benefit
over the placebo, it may be premature to discard this ap-
proach [113]. It is increasingly apparent that there are
distinct CRPS populations, so subgroups of patients with
elevated pro-inflammatory cytokine levels may stand to
benefit from a trial of this treatment.
Hyperbaric oxygen therapy
The anti-nociceptive effect of hyperbaric oxygen therapy
(HBOT) has been well-documented in animal models.
This is conferred via neural nitric oxide-dependent release
of the endogenous opioid, dynorphin, which subsequently
activates k- and μ-opioid receptors [114]. A RCT was
designed to evaluate the efficacy of HBOT in treating 71
patients with post-traumatic CRPS of the wrist [115]. In
this study, patients receiving 15 daily 90-min HBOT
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sessions demonstrated substantially lower visual analogue
scale (VAS) scores 45 days following treatment. Pain relief
occurred rapidly with marked improvements in VAS
scores evident by the end of the first day. Moreover,
HBOT was shown to be effective at reducing oedema and
improving range of motion. However, it is important to
note that the generalization of these findings must be
treated with caution since treatment was commenced
within a month and a half of the initial injury. As such,
further work is necessary to replicate the beneficial effects
of this approach in patients with more chronic injuries.
Botulinum toxin-A (BTX-A)
BTX-A has been shown to confer pain relief in neuro-
pathic pain, which complicates disorders of the central
and peripheral nervous system and may therefore demon-
strate efficacy in managing CRPS. Kharkar et al. investi-
gated the efficacy of BTX-A in providing pain relief in 37
subjects with CRPS suffering from focal tonic dystonia
[116]. In this study, 97% of patients reported significant
pain relief with a 43% reduction in the mean pain score
after 4 weeks of treatment. Although this was a retrospect-
ive study lacking a control group, the results are promis-
ing and call for further clinical trials. It is important to
note that despite the growing use of BTX-A in clinical
practice, there is still limited information to guide the
choice, formulation and dose of the toxin, which are
mainly based on the experience of the clinician.
Plasma exchange
Recent developments in the understanding of the auto-
immune aetiology of CRPS have highlighted the potential
use of plasma exchange therapy, which has demonstrated
benefit in other autoimmune disorders. A retrospective
case series of 33 patients with CRPS receiving plasma
exchange was conducted by Aradillas et al. to assess this
approach [117]. In this case series, 91% of patients re-
ported a significant median pain reduction of 64% follow-
ing therapy. Additionally, weekly treatment was shown to
be successful in maintaining pain relief in 45% of patients.
This study advocates large, randomised placebo-controlled
trials to validate and expand on the findings.
Future therapy
As our understanding of the pathophysiology of CRPS
continues to grow, so too does the scope for the finding
of new or existing agents to target the different disease
mechanisms. The neurogenic inflammation that occurs
in CRPS can be attributed in part to the activation of
microglia, which is mediated by Toll-like receptor (TLR)
signalling. Naltrexone has antagonistic effects at the
TLR-4 and hypothetically suppress inflammation. A
recent case series of two patients found low-dose nal-
trexone to be effective in reducing pain with minimal
side effects and a RCT is currently ongoing to investi-
gate this further [118, 119].
In neuropathic pain models, activated microglia
express cannabinoid receptor-2 (CB-2) and chemokine
fractalkine receptor (CX3CR1) [120, 121]. Both receptors
play a significant role in microglial activation and neuro-
inflammation, and it is hypothesised that regulating the
signalling of these two receptors with a CB2 agonist
could modulate the pain and inflammation. In the rat
model of CRPS, the novel CB2 agonist MDA7 was found
to suppress peripheral oedema, microglial activation and
receptor expression in the spinal cord, thereby corrobor-
ating the hypothesis [122]. Human studies are necessary
to elucidate the efficacy of this agent in treating CRPS.
NSAIDs and corticosteroids have been used in CRPS
with the aim of limiting pain and inflammation. The
novel anti-inflammatory agent, polydeoxyribonucleotide
is a low molecular weight deoxyribonucleic acid complex
that acts as a selective agonist against the adenosine
A2A receptor. This leads to a decrease in the secretion
of inflammatory cytokines such as TNF-α, macrophage
inflammatory protein 1α and IL-6 along with an increase
in IL-10 [123]. Furthermore, activation of this receptor
induces endothelial cell proliferation and migration to
promote tissue regeneration [124, 125]. In a recently
published case report, polydeoxyribonucleotide treat-
ment was associated with rapid pain relief, which under-
lines the potential of this approach [126].
Conclusion
Future prospects
Although there has yet to be a successful treatment for
CRPS to date, years of research have provided us with
many valuable lessons and our understanding of this
condition continues to grow. It is evident that a CRPS
population is heterogeneous, with distinct subgroups
that exhibit different clinical and biochemical features,
thereby exhibiting a varying response to treatment.
Moreover, the evidence-base regarding CRPS type II
remains scarce in contrast to CRPS type I. Hence, future
work is needed to elucidate the subgroups of patients
who would benefit the most from currently available
treatment. Given the complex nature of this syndrome,
it is unlikely that targeting a specific mechanism will be
effective. As with other chronic disorders, the future of
CRPS treatment may lie in combination therapy and
studies investigating this will be necessary.
Summary
The complex pathophysiology of CRPS remains a
challenge for clinicians and researchers alike in develop-
ing treatments to successfully combat this severe, life-
threatening condition. Due to the multifactorial nature
of this condition, animal models that can simulate the
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disease process are lacking, which is further com-
pounded by our limited understanding of the mecha-
nisms involved. This has hindered the development of
new therapies, leading clinicians to adopt a trial and
error approach towards managing this syndrome. Hence,
the majority of studies evaluating novel approaches have
been restricted to case series or small pilot studies. The
recent declaration by the United States Food and Drug
Administration of CRPS as an official disease has given
us renewed hope, as this has been a catalyst for new
drug development.
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